ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 572,58
-0,79%
Dow Jones
40 211,72
0,00%
DAX
18 489,85
-0,59%
Brent Oil
82,94
-1,66%
Bitcoin
63 964,17
-1,37%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
25/10/200723h06Edgar (US Regulatory)Allos Therapeutics Inc - Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
25/10/200722h01PR Newswire (US)Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/10/200722h58Edgar (US Regulatory)Allos Therapeutics Inc - Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/10/200713h55PR Newswire (US)Allos Therapeutics to Report 2007 Third Quarter Financial Results on November 5, 2007NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
26/09/200716h43Edgar (US Regulatory)Allos Therapeutics Inc (Other) (SC 13G)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/09/200721h35Edgar (US Regulatory)Allos Therapeutics Inc (Other) (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
24/09/200713h30PR Newswire (US)Interim Response and Safety Analyses Support Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in PatientsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/09/200714h00PR Newswire (US)Allos Therapeutics to Present at the 2007 UBS Global Life Sciences ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/09/200714h00PR Newswire (US)Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/08/200714h00PR Newswire (US)Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/08/200715h00PR Newswire (US)Allos Therapeutics Reports Second Quarter 2007 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
18/07/200714h00PR Newswire (US)Allos Therapeutics to Report 2007 Second Quarter Financial Results on August 7, 2007NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
25/06/200715h30PR Newswire (US)Allos Therapeutics Selected to Join Russel 3000 IndexNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/06/200712h30PR Newswire (US)Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From BreastNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
31/05/200723h01PR Newswire (US)Allos Therapeutics Initiates Phase I/II Study of PDX and Gemcitabine in Patients With Non-Hodgkin's Lymphoma or Hodgkin's DiseasNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/05/200723h55PR Newswire (US)Allos Therapeutics Files Shelf Registration StatementNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/05/200714h30PR Newswire (US)Allos Therapeutics Reports First Quarter 2007 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/05/200719h21PR Newswire (US)Allos Therapeutics to Announce 2007 First Quarter Results on Tuesday, May 8NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
26/04/200714h00PR Newswire (US)Allos Therapeutics Appoints Dr. Jeffrey R. Latts to Its Board of DirectorsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/04/200714h30PR Newswire (US)Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European CommissionNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/03/200713h00PR Newswire (US)Allos Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Medical OfficerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/03/200713h00PR Newswire (US)Allos Therapeutics Reports Fourth Quarter and 2006 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
27/02/200714h00PR Newswire (US)Allos Therapeutics to Report 2006 Fourth Quarter Financial Results on Monday, March 5NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/02/200714h00PR Newswire (US)Allos Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/02/200717h01PR Newswire (US)Allos Therapeutics Announces Closing of Common Stock OfferingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/01/200712h00PR Newswire (US)Allos Therapeutics Announces Pricing of Underwritten Offering of 9,000,000 Shares of Common StockNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/01/200721h19PR Newswire (US)Allos Therapeutics to Present at the 2007 JP Morgan Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/01/200713h05PR Newswire (US)Allos Therapeutics Appoints William R. Ringo to Its Board of DirectorsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/01/200713h00PR Newswire (US)Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 Trial of Its Novel Antifolate PDX in PatienNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/12/200617h46PR Newswire (US)Results Reported at the American Society of Hematology Annual Meeting Affirm Impressive Activity of Allos Therapeutics' Novel AnNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Dernières Valeurs Consultées

NYSE
DIS
Walt Disney
USI
USTECH100
US Tech 100
NASDAQ
AAPL
Apple
NYSE
MRK
Merck
EU
BN
Danone
FTSE
UKX
FTSE 100
COIN
BTCUSD
Bitcoin
NYSE
KO
Coca Cola
EU
VIV
Vivendi
EU
CAP
Capgemini
NASDAQ
AMZN
Amazon.com
EU
PX1
CAC 40
EU
ORA
Orange
EU
ACA
Credit Agricole
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés